Induced pluripotent stem cells

An emerging theranostics platform

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Nuclear reprogramming generates induced pluripotent stem (iPS) cells endowed with the unlimited potential to reconstruct genetically identical tissues. This biomedical tool offers unprecedented opportunities to develop scalable yet personalized cell-based reagents. The emerging platform of regenerative theranostics provides a unique approach to expose mechanisms of disease etiology in the context of dysfunctional cell biology. Resolved molecular dynamics that define and regulate the regenerative capacity of individual stem cells will enable next-generation, patient-specific diagnostic and therapeutic applications.

Original languageEnglish (US)
Pages (from-to)648-650
Number of pages3
JournalClinical Pharmacology and Therapeutics
Volume89
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Induced Pluripotent Stem Cells
Molecular Dynamics Simulation
Cell Biology
Stem Cells
Therapeutics
Theranostic Nanomedicine
Cellular Reprogramming

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Induced pluripotent stem cells : An emerging theranostics platform. / Nelson, Timothy J; Terzic, Andre.

In: Clinical Pharmacology and Therapeutics, Vol. 89, No. 5, 05.2011, p. 648-650.

Research output: Contribution to journalArticle

@article{4cb611b605224c7ab58b8a03a2c3b538,
title = "Induced pluripotent stem cells: An emerging theranostics platform",
abstract = "Nuclear reprogramming generates induced pluripotent stem (iPS) cells endowed with the unlimited potential to reconstruct genetically identical tissues. This biomedical tool offers unprecedented opportunities to develop scalable yet personalized cell-based reagents. The emerging platform of regenerative theranostics provides a unique approach to expose mechanisms of disease etiology in the context of dysfunctional cell biology. Resolved molecular dynamics that define and regulate the regenerative capacity of individual stem cells will enable next-generation, patient-specific diagnostic and therapeutic applications.",
author = "Nelson, {Timothy J} and Andre Terzic",
year = "2011",
month = "5",
doi = "10.1038/clpt.2010.304",
language = "English (US)",
volume = "89",
pages = "648--650",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Induced pluripotent stem cells

T2 - An emerging theranostics platform

AU - Nelson, Timothy J

AU - Terzic, Andre

PY - 2011/5

Y1 - 2011/5

N2 - Nuclear reprogramming generates induced pluripotent stem (iPS) cells endowed with the unlimited potential to reconstruct genetically identical tissues. This biomedical tool offers unprecedented opportunities to develop scalable yet personalized cell-based reagents. The emerging platform of regenerative theranostics provides a unique approach to expose mechanisms of disease etiology in the context of dysfunctional cell biology. Resolved molecular dynamics that define and regulate the regenerative capacity of individual stem cells will enable next-generation, patient-specific diagnostic and therapeutic applications.

AB - Nuclear reprogramming generates induced pluripotent stem (iPS) cells endowed with the unlimited potential to reconstruct genetically identical tissues. This biomedical tool offers unprecedented opportunities to develop scalable yet personalized cell-based reagents. The emerging platform of regenerative theranostics provides a unique approach to expose mechanisms of disease etiology in the context of dysfunctional cell biology. Resolved molecular dynamics that define and regulate the regenerative capacity of individual stem cells will enable next-generation, patient-specific diagnostic and therapeutic applications.

UR - http://www.scopus.com/inward/record.url?scp=79955401698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955401698&partnerID=8YFLogxK

U2 - 10.1038/clpt.2010.304

DO - 10.1038/clpt.2010.304

M3 - Article

VL - 89

SP - 648

EP - 650

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -